Annual General Meeting of Shareholders in Biacore International AB

UPPSALA, Sweden, April 28, 2004 (PRIMEZONE) -- Biacore International AB (Biacore) (Stockholmsborsen: BCOR) (Nasdaq:BCOR) today announced that today's annual general meeting was attended by 25 shareholders, representing 53 percent of the total number of shares and votes in the company.

The meeting decided, in accordance with the board of directors' and the president's proposal that the non-restricted equity in the parent company at the meeting's disposal, in total SEK 137,021,000, be used as follows:

 Dividend to shareholders, SEK 3 per share    SEK    29,250,000
 To be carried forward as retained earnings   SEK  107,771,000
 Total                                        SEK  137,021,000

The meeting reelected the board members Mr Lars-Goran Andren, Dr Gordon Edge, Mr Tom Erixon, Dr Ulf Jonsson, Mr Donald R Parfet, Mr Mats Pettersson and Dr Marc Van Regenmortel and elected Mrs Donna Janson as new member of the board. The unions had nominated Mrs Anna Hansson and Dr Markku Hamalainen as their representatives on the board and Mr Hans Sjobom and Mrs Anette Persson as deputies.

The meeting decided that an auditing firm should be appointed auditor, that remuneration should be paid pursuant to approved invoice ant that the auditing firm PricewaterhouseCoopers AB be re-elected for the period up until the end of the annual general meeting of shareholders held during the year 2008.

The meeting decided to authorise the chairman of the board to convene representatives of at least the three, as per 30 September each year, largesst owners of the company, who are not directors of the board, to be members of the nominations committee together with the chairman of the board for the time until the next annaul general meeting of shareholders. Should any of the aforementioned owners abstain from participation in the nominatins committee, the next owner in terms of size shall be asked to participate instead. When it constitutes itself, the committee shall elect a chairman for the committee. The composition of the committee shall be announced in connection with publication of the company's interim report for the third quarter each year. The members of the committee shall receive no remuneration. Before the annual general meeting of shareholders, the nominations committee shall make proposals on the number of board directors and deputy board directors, remuneration to the board and election of board directors and, where appropriate, deputy board directors and remuneration for and election of auditors.

- Ends -

Cautionary Statement

This press release contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, which, by their nature, involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

About Biacore

Biacore is a global market leader in Surface Plasmon Resonance (SPR) technology based systems with its own sales operations in the U.S., across Europe, Japan, Australia and New Zealand. A strong patent portfolio protects Biacore's SPR technology, which gives unique real- time insights into biomolecular interactions. Target groups for the Company's products consist primarily of medical and life science research laboratories and pharmaceutical and biotechnology companies around the world. Biacore is focusing on drug discovery and development as its prime areas for future growth. The Company currently has seven systems on the market, the most important of which are: Biacore(R)S51 for applications downstream of high-throughput screening (HTS) including rapid characterization of HTS hits and comprehensive pre-clinical evaluation of lead compounds, Biacore(R)3000, which offers flexibility in key life science research and drug discovery applications upstream of HTS, and Biacore(R)C which is specifically designed for compliant concentration analysis of biopharmaceuticals in GLP/GMP applications. A new SPR array system, which will provide higher information content, is expected to reach the market in 2004.

Based in Uppsala, Sweden, the Company is listed on Stockholmsborsen and Nasdaq in the U.S. In 2003 the Company had sales of SEK 515.5 million and an operating income of SEK 29.5 million.

Further information on Biacore can be found on the web:

 For further information, please contact: 
 Jan Isoz, Investor Relations 
 +46 70 81 03 117

 Scientific/Trade Press Enquiries 
 Sarah Perceval, De Facto Communications 
 Michaela Mahon, De Facto Communications 
 +44 (0) 207 496 3300

This information was brought to you by Waymaker